Global Percutaneous Coronary Intervention Market Research Report Forecast to 2023




Percutaneous coronary intervention (PCI) is a procedure used to treat the narrowing of coronary arteries. In this procedure, a catheter is used to place a small structure, i.e., a stent to open blood vessels in the heart that have been narrowed owing to plaque build-up. Factors such as the growing prevalence of cardiac diseases, the rising preference for minimally invasive procedures, and growing geriatric population are anticipated to propel the growth of the market over the forecast period.
Factors such as the rising prevalence of heart diseases and increasing preference for minimally invasive procedures are expected to fuel the demand for percutaneous coronary intervention. The increasing geriatric population is also propelling the growth of the market. However, the risk of infection and stringent government regulations are the major challenges for the market.
The global market for percutaneous coronary intervention has been segmented on the basis of product type, end user, and region. On the basis of product type, the market has been divided into coronary stents, PTCA catheters, and coronary guidewire and accessories. Coronary stents are further sub-segmented into drug-eluting stents, bare metal stents, and bioresorbable vascular scaffolds. PTCA catheters are further sub-segmented into balloon catheter and guiding catheter. By accessories, the product type segment is further categorized into inflation devices, torquer, RHV (Y-connector), control syringe, manifold, extension line, and others.
Based on end user, the market has been divided into hospitals and specialty clinics, ambulatory surgical centers, research and academic institutes, and others.
The global percutaneous coronary intervention market accounted for USD 8,679.1 million in 2015 and is expected to register a CAGR of 7.10 % during the forecast period.

Key Players
Some of the key players for the global percutaneous coronary intervention market are Abbott, ASAHI INTECC Company Limited, B. Braun Melsungen AG, Biosensors International Group, Ltd., BIOTRONIK, Boston Scientific Corporation, C. R. Bard, Inc, Comed B.V., Cook, Cordis, Medtronic Plc, Meril Lifesciences Pvt. Ltd, Merit Medical System, Terumo Corporation, and others.
Study Objectives
• To provide a detailed analysis of the market structure along with the forecast of various segments and sub-segments of the global percutaneous coronary intervention market
• To provide insights into factors influencing and affecting market growth
• To provide historical, current, and forecast revenue of market segments based on product type and end user
• To provide historical, current, and forecast revenue of market segments and sub-segments with respect to regional markets and key countries
• To provide strategic profiling of key players in the market, comprehensively analyzing their market shares, core competencies, and drawing a competitive landscape for the market
• To provide economic factors, technology trends, and market trends that influence the global percutaneous coronary intervention market

Target Audience
• Global percutaneous coronary intervention solution providers, manufacturers, and suppliers
• Research and development (R&D) companies
• Market research and consulting service providers
• Academic institutes and universities

Key Findings
• The global percutaneous coronary intervention market is expected to reach a value of USD 15,205.4 million by 2023 at a CAGR of 7.10%.
• On the basis of product type, the coronary stents segment is projected to be largest, registering a CAGR of 7.81% during the forecast period.
• By end user, the hospitals and clinics segment is expected to be the largest at USD 6,680.0 million by 2023.
• On the basis of region, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas market is expected to be the largest at an estimated value of USD 6,068.7 million by 2023.
• Asia-Pacific is projected to be the fastest-growing market at a CAGR of 8.14% from 2018 to 2023.
Regional Analysis
• Americas
o North America
 US
 Canada
o South America
• Europe
o Western Europe
 Germany
 France
 UK
 Italy
 Spain
 Rest of Europe
o Eastern Europe
• Asia-Pacific
o Japan
o China
o India
o South Korea
o Australia
o Rest of Asia-Pacific
• Middle East & Africa
o Middle East
o Africa

Table of Contents

Table of Contents:

1 Report Prologue
2 Executive Summary
3 Introduction
3.1 Definition
3.2 Scope of the Study
3.3 Assumptions & Limitations
3.4 Market Structure
4 Research Methodology
4.1 Research Process
4.2 Primary Research
4.3 Secondary Research
4.4 Market Size Estimation
4.5 Forecast Model
5 Market Dynamics
5.1 Introduction
5.2 Drivers
5.2.1 Rising prevalence of heart diseases
5.2.2 Increasing preference for minimally invasive procedures
5.2.3 Increasing geriatric population
5.3 Restraints
5.3.1 Risk of infection
5.3.2 Stringent government regulations
5.4 Opportunities
5.4.1 Favorable Reimbursement Scenario
6 Market Factor Analysis
6.1 Value Chain Analysis
6.1.1 Research and Development
6.1.2 Manufacturing
6.1.3 Distribution & Sales
6.1.4 Post-Sales Monitoring
6.2 Porter’s Five Forces Model
6.2.1 Bargaining Power of Suppliers
6.2.2 Bargaining Power of Buyers
6.2.3 Threat of New Entrants
6.2.4 Threat of Substitutes
6.2.5 Intense Rivalry
6.3 Investment Opportunity Analysis
6.4 Pricing Analysis
6.5 Market Volume by Product Type
7 Global Percutaneous Coronary Intervention Market by Product Type
7.1 Overview
7.2 Coronary Stents
7.3 PTCA Catheters
7.4 Coronary Guidewire
7.5 Accessories
8 Global Percutaneous Coronary Intervention Market by End-user
8.1 Overview
8.2 Hospitals & Specialty Clinics
8.3 Ambulatory Surgical Centers
8.4 Research and Academic Institutes
8.5 Others
9 Global Percutaneous Coronary Intervention Market by Region
9.1 Overview
9.2 Americas
9.2.1 North America US Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe Germany France UK Italy Spain Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 South Korea
9.4.5 Australia
9.4.6 Rest of Asia-Pacific
9.5 Middle East & Africa
9.5.1 Middle East
9.5.2 Africa
10 Competitive Landscape
10.1 Introduction
10.2 Company Market Share Analysis
11 Company Profile
11.1 Abbott
11.1.1 Company Overview
11.1.2 Financial Overview
11.1.3 Products Offering
11.1.4 SWOT Analysis
11.1.5 Key Developments
11.1.6 Key strategy
11.2 ASAHI INTECC Company Limited
11.2.1 Company Overview
11.2.2 Financial Overview
11.2.3 Key Developments
11.2.4 SWOT Analysis
11.2.5 Key Strategy
11.3 B. Braun Melsungen AG
11.3.1 Company Overview
11.3.2 Financial Overview
11.3.3 Products Offering
11.3.4 SWOT Analysis
11.3.5 Key Developments
11.3.6 Key strategy
11.4 Biosensors International Group, Ltd.
11.4.1 Company Overview
11.4.2 Financial Overview
11.4.3 Products Offering
11.4.4 SWOT Analysis
11.4.5 Key Developments
11.4.6 Key strategy
11.5.1 Company Overview
11.5.2 Products Offering
11.5.3 SWOT Analysis
11.5.4 Key Developments
11.5.5 Key strategy
11.6 Boston Scientific Corporation
11.6.1 Company Overview
11.6.2 Financial Overview
11.6.3 Products Offering
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.6.6 Key Strategy
11.7 C. R. Bard, Inc.
11.7.1 Company Overview
11.7.2 Financial Overview
11.7.3 Products Offering
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.7.6 Key Strategy
11.8 Comed B.V.
11.8.1 Company Overview
11.8.2 Financial Overview
11.8.3 Products Offering
11.8.4 SWOT Analysis
11.8.5 Key Developments
11.8.6 Key Strategy
11.9 Cook
11.9.1 Company Overview
11.9.2 Financial Overview
11.9.3 Products Offering
11.9.4 SWOT Analysis
11.9.5 Key Developments
11.9.6 Key Strategy
11.1 Cordis
11.10.1 Company Overview
11.10.2 Financial Overview
11.10.3 Products Offering
11.10.4 SWOT Analysis
11.10.5 Key Development
11.10.6 Key Strategy
11.11 Medtronic Plc
11.11.1 Company Overview
11.11.2 Financial Overview
11.11.3 Products Offering
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.11.6 Key Strategy
11.12 Meril Lifesciences Pvt. Ltd
11.12.1 Company Overview
11.12.2 Financial Overview
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.12.6 Key Strategy
11.13 Merit Medical System
11.13.1 Company Overview
11.13.2 Financial Overview
11.13.3 Products Offering
11.13.4 Key Developments
11.13.5 SWOT Analysis
11.13.6 Key Strategy
11.14 Terumo Corporation
11.14.1 Company Overview
11.14.2 Financial Overview
11.14.3 Products Offering
11.14.4 Key Developments
11.14.5 SWOT Analysis
11.14.6 Key Strategy
12 Appendix
12.1 Discussion Blue Print

Additional information


Geography Covered

Date Published